One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Prednisone in systemic lupus erythematosus: taper quickly, withdraw slowly
Guillermo Ruiz-Irastorza
doi : 10.1093/rheumatology/keab347
Rheumatology, Volume 60, Issue 12, December 2021, Pages 5489–5490
Vedolizumab-associated enthesitis: correlation or causality?
Francesco Vitali, David Simon, Markus F Neurath, Georg Schett, Sebastian Zundler
doi : 10.1093/rheumatology/keab396
Rheumatology, Volume 60, Issue 12, December 2021, Pages 5491–5492
In the limelight: AA amyloidosis exposes TNF receptor-1 associated periodic syndrome
Giulio Cavalli, Corrado Campochiaro, Lorenzo Dagna
doi : 10.1093/rheumatology/keab540
Rheumatology, Volume 60, Issue 12, December 2021, Pages 5493–5494
Call for emergency action to limit global temperature increases, restore biodiversity and protect health
Lukoye Atwoli, Abdullah H Baqui, Thomas Benfield, Raffaella Bosurgi, Fiona Godlee, Stephen Hancocks, Richard Horton, Laurie Laybourn-Langton, Carlos Augusto Monteiro, Ian Norman, Kirsten Patrick, Nigel Praities, Marcel G M Olde Rikkert, Eric J Rubin, Peush Sahni, Richard Smith, Nick Talley, Sue Turale, Damián Vázquez
doi : 10.1093/rheumatology/keab640
Rheumatology, Volume 60, Issue 12, December 2021, Pages 5495–5497
A review and roadmap of the skin, lung and gut microbiota in systemic sclerosis
Shannon Teaw, Monique Hinchcliff, Michelle Cheng
doi : 10.1093/rheumatology/keab262
Rheumatology, Volume 60, Issue 12, December 2021, Pages 5498–5508
As our understanding of the genetic underpinnings of SSc increases, questions regarding the environmental trigger(s) that induce and propagate SSc in the genetically predisposed individual emerge. The interplay between the environment, the immune system, and the microbial species that inhabit the patient’s skin and gastrointestinal tract is a pathobiological frontier that is largely unexplored in SSc. The purpose of this review is to provide an overview of the methodologies, experimental study results and future roadmap for elucidating the relationship between the SSc host and his/her microbiome.
ANCA in systemic sclerosis, when vasculitis overlaps with vasculopathy: a devastating combination of pathologies
Michael Hughes, Bashar Kahaleh, Christopher P Denton, Justin C Mason, Marco Matucci-Cerinic
doi : 10.1093/rheumatology/keab278
Rheumatology, Volume 60, Issue 12, December 2021, Pages 5509–5516
In patients with SSc, the coexistence of ANCA-associated vasculitis (SSc-AAV) has been reported to be associated with a severe disease course, including significant pulmonary and renal involvement. The presence of ANCA is not uncommon in patients with SSc, and therefore clinicians must maintain a high index of clinical suspicion about SSc-AAV. p-ANCA and anti-myeloperoxidase antibodies are the most common antibodies observed. Patients typically present with clinical features of microscopic polyangiitis or renal-limited vasculitis. There are multiple areas of potential interaction in the pathogenesis of SSc and AAV, which can exacerbate/compound vascular disease. In addition, similar patterns of major internal organ involvement (e.g. lung and kidneys) are seen in both conditions. We highlight a diagnostic approach to SSc-AAV and the paucity of data to inform management. As such, SSc-AAV is typically treated as per isolated AAV, which can potentially be hazardous in patients with SSc (e.g. due to the association between high-dose steroid and scleroderma renal crisis). We propose that this rare clinical entity warrants rigorous investigation, including definition of a therapeutic strategy to ameliorate the potentially devastating combination of pathologies in SSc-AAV.
Low-dose glucocorticoids should be withdrawn or continued in systemic lupus erythematosus? A systematic review and meta-analysis on risk of flare and damage accrual
Lanlan Ji, Wenhui Xie, Zhuoli Zhang
doi : 10.1093/rheumatology/keab149
Rheumatology, Volume 60, Issue 12, December 2021, Pages 5517–5526
To assess the risk of flare and damage accrual after discontinuation of low-dose glucocorticoids (GCs) in SLE.
Anakinra in hospitalized non-intubated patients with coronavirus disease 2019: a Systematic review and meta-analysis
Fotios Barkas, Sebastian Filippas-Ntekouan, Maria Kosmidou, Evangelos Liberopoulos, Angelos Liontos, Haralampos Milionis
doi : 10.1093/rheumatology/keab447
Rheumatology, Volume 60, Issue 12, December 2021, Pages 5527–5537
Acute respiratory distress syndrome and cytokine release syndrome are the major complications of coronavirus disease 2019 (COVID-19) associated with increased mortality risk. We performed a meta-analysis to assess the efficacy and safety of anakinra in adult hospitalized non-intubated patients with COVID-19.
Autologous haematopoietic stem cell transplantation restores the suppressive capacity of regulatory B cells in systemic sclerosis patients
João R Lima-Júnior, Lucas C M Arruda, Maynara S Gonçalves, Juliana B E Dias, Daniela A Moraes, Dimas T Covas, Belinda P Simões, Maria Carolina Oliveira, Kelen C R Malmegrim
doi : 10.1093/rheumatology/keab257
Rheumatology, Volume 60, Issue 12, December 2021, Pages 5538–5548
The rationale of autologous haematopoietic stem cell transplantation (AHSCT) for autoimmune diseases is that high-dose immunosuppression eradicates autoreactive T and B cells and the infused autologous haematopoietic stem cells promote reconstitution of a naïve and self-tolerant immune system. The aim of this study was to evaluate the reconstitution of different B cell subsets, both quantitatively and functionally, in SSc patients treated with AHSCT.
Doppler ultrasound predicts successful discontinuation of biological DMARDs in rheumatoid arthritis patients in clinical remission
Lene Terslev, Cecilie Heegaard Brahe, Merete Lund Hetland, Stylianos Georgiadis, Karen Ellegaard, Lars Juul, Tuan Huynh, Uffe Møller Døhn, Viktoria Fana, Torsten Møller, Simon Krabbe, Lykke Midtbøll Ørnbjerg, Daniel Glinatsi, Henrik Røgind, Anette Hansen, Jesper Nørregaard, Søren Jacobsen, Dorte Vendelbo Jensen, Natalia Manilo, Karsten Asmussen, Mikael Boesen, Zoreh Rastiemadabadi, Lone Morsel-Carlsen, Jakob Møllenbach Møller, Niels Steen Krogh, Mikkel Østergaard
doi : 10.1093/rheumatology/keab276
Rheumatology, Volume 60, Issue 12, December 2021, Pages 5549–5559
To assess the ability of ultrasound to predict successful tapering and successful discontinuation of biological DMARDs (bDMARDs) at the 2-year follow-up in RA patients in sustained remission.
Patients with psychiatric diagnoses have lower quality of life than other patients with juvenile rheumatic disease: a prospective study
Silja Kosola, Heikki Relas
doi : 10.1093/rheumatology/keab150
Rheumatology, Volume 60, Issue 12, December 2021, Pages 5560–5566
Transition of adolescents with chronic diseases from paediatric healthcare to adult care requires attention to maintain optimal treatment results. We examined changes in health-related quality of life (HRQoL) and disease activity among JIA patients with or without concomitant psychiatric diagnoses after transfer to an adult clinic.
Type 2 diabetes mellitus, glycaemic control, associated therapies and risk of rheumatoid arthritis: a retrospective cohort study
Dawit T Zemedikun, Krishna Gokhale, Joht Singh Chandan, Jennifer Cooper, Janet M Lord, Andrew Filer, Marie Falahee, Krishnarajah Nirantharakumar, Karim Raza
doi : 10.1093/rheumatology/keab148
Rheumatology, Volume 60, Issue 12, December 2021, Pages 5567–5575
To compare the incident risk of RA in patients with type 2 diabetes mellitus (T2DM) and to explore the role of glycaemic control and associated therapeutic use in the onset of RA.
Should we use glucocorticoids in early rheumatoid arthritis? Results at 5 years from the early RA UCLouvain Brussels cohort
Emilie Sapart, Tatiana Sokolova, Stéphanie de Montjoye, Stéphanie Dierckx, Adrien Nzeusseu, Aleksandra Avramovska, Patrick Durez
doi : 10.1093/rheumatology/keab151
Rheumatology, Volume 60, Issue 12, December 2021, Pages 5576–5582
To evaluate the proportion of patients with early RA (ERA) who had or had not initiated glucocorticoids, to analyse the baseline characteristics, and to assess the clinical benefit and side effects of glucocorticoids during 5?years of follow-up.
Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE
Vibeke Strand, Namita Tundia, Martin Bergman, Andrew Ostor, Patrick Durez, In-Ho Song, Jeffrey Enejosa, Casey Schlacher, Yan Song, Roy Fleischmann
doi : 10.1093/rheumatology/keab158
Rheumatology, Volume 60, Issue 12, December 2021, Pages 5583–5594
To evaluate the impact of upadacitinib vs placebo and adalimumab treatment, on patient-reported outcomes (PROs) in SELECT-COMPARE in an active RA population with inadequate responses to MTX (MTX-IR).
Thymus variants on imaging in patients with rheumatoid arthritis—clinical and immunological significance
Okinori Murata, Katsuya Suzuki, Hiroaki Sugiura, Yasushi Kondo, Masaru Takeshita, Keiko Koga, Maiko Takiguchi, Rina Kurisu, Yoshiaki Kassai, Hidekata Yasuoka, Kunihiro Yamaoka, Rimpei Morita, Akihiko Yoshimura, Tsutomu Takeuchi
doi : 10.1093/rheumatology/keab164
Rheumatology, Volume 60, Issue 12, December 2021, Pages 5595–5600
We sought to clarify the presence of radiographic thymus variants using a scoring system, and their association with clinical and immunological features in RA patients.
Identifying unmet needs in SSc-ILD by semi-qualitative in-depth interviews
Anna-Maria Hoffmann-Vold, Elisabeth Bendstrup, Theodoros Dimitroulas, Roger Hesselstrand, Antonio Morais, Ritva Peltomaa, Vanessa Smith, Joep Welling, Madelon C Vonk, Wim A Wuyts
doi : 10.1093/rheumatology/keab154
Rheumatology, Volume 60, Issue 12, December 2021, Pages 5601–5609
Interstitial lung disease is frequent in SSc (SSc-ILD) and associates with significantly reduced quality of life. Here we aimed to analyse patient pathways, and experiences of patients and healthcare providers (HCPs) in order to identify unmet needs in the management of SSc-ILD patients.
Are remission and low disease activity state ideal targets for pregnancy planning in systemic lupus erythematosus? A multicentre study
Chiara Tani, Dina Zucchi, Isabell Haase, Maddalena Larosa, Francesca Crisafulli, Francesca A L Strigini, Francesca Monacci, Elena Elefante, Johanna Mucke, May Y Choi, Laura Andreoli, Luca Iaccarino, Angela Tincani, Andrea Doria, Rebecca Fischer-Betz, Marta Mosca
doi : 10.1093/rheumatology/keab155
Rheumatology, Volume 60, Issue 12, December 2021, Pages 5610–5619
To determine whether disease remission or low disease activity state at the beginning of pregnancy in SLE patients is associated with better pregnancy outcome.
Psychosis in systemic lupus erythematosus (SLE): 40-year experience of a specialist centre
Esha Abrol, Ester Coutinho, Michael Chou, Melanie Hart, Angela Vincent, Robert Howard, Michael S Zandi, David Isenberg
doi : 10.1093/rheumatology/keab160
Rheumatology, Volume 60, Issue 12, December 2021, Pages 5620–5629
The long-term outcome of psychosis in association with systemic lupus erythematosus (SLE) has been insufficiently characterised. We used a specialist centre cohort of patients with SLE and psychosis to investigate their clinical outcome and phenotypic and laboratory characteristics.
‘It is good to have a target in mind’: qualitative views of patients and parents informing a treat to target clinical trial in juvenile-onset systemic lupus erythematosus
Eve M D Smith, Sarah L Gorst, Eslam Al-Abadi, Daniel P Hawley, Valentina Leone, Clarissa Pilkington, Athimalaipet V Ramanan, Satyapal Rangaraj, Arani Sridhar, Michael W Beresford, Bridget Young
doi : 10.1093/rheumatology/keab173
Rheumatology, Volume 60, Issue 12, December 2021, Pages 5630–5641
We sought to explore patient and parental views on treatment targets, outcome measures and study designs being considered for a future JSLE treat-to-target (T2T) study.
Familial Mediterranean fever and asthma
Avishai M Tsur, Abdulla Watad, Omer Gendelman, Daniel Nissan, Arnon D Cohen, Howard Amital
doi : 10.1093/rheumatology/keab159
Rheumatology, Volume 60, Issue 12, December 2021, Pages 5642–5646
This study was designed as a cross-sectional study. All patients diagnosed with FMF between 1 January 2000 and 31 December 2016 who were prescribed colchicine were included in the study. Controls were matched by sex, date of birth, residential socioeconomic status and country of birth. Logistic regression models were used to determine the odds ratio for asthma in FMF patients and controls.
Utility of lymphocyte phenotype profile to differentiate primary Sjögren’s syndrome from sicca syndrome
José Loureiro-Amigo, Carlos Palacio-García, Mónica Martínez-Gallo, Fernando Martínez-Valle, Marc Ramentol-Sintas, Roser Soláns-Laqué
doi : 10.1093/rheumatology/keab170
Rheumatology, Volume 60, Issue 12, December 2021, Pages 5647–5658
To assess the potential diagnostic utility of advanced lymphocyte profiling to differentiate between primary Sjögren’s Syndrome (pSS) and non-Sjögren Sicca syndrome.
Pulmonary findings on high-resolution computed tomography in Takayasu arteritis
Xiufang Kong, Jing Zhang, Jiang Lin, Peng Lv, Huiyong Chen, Zongfei Ji, Xiaomin Dai, Xuejuan Jin, Lili Ma, Lindi Jiang
doi : 10.1093/rheumatology/keab163
Rheumatology, Volume 60, Issue 12, December 2021, Pages 5659–5667
This study aimed to describe pulmonary high-resolution CT (HRCT) findings in Takayasu arteritis (TA) and to determine possible causes.
Incidence of Paget’s disease of bone in the UK: evidence of a continuing decline
Michael J Cook, Stephen R Pye, Mark Lunt, William G Dixon, Darren M Ashcroft, Terence W O’Neill
doi : 10.1093/rheumatology/keab232
Rheumatology, Volume 60, Issue 12, December 2021, Pages 5668–5676
To characterize the incidence of clinically diagnosed Paget’s disease of bone in the UK during 1999–2015 and to determine variations in the incidence of disease by age, sex, geography and level of deprivation.
The burden of psoriatic arthritis in the biologics era: data from the Belgian Epidemiological Psoriatic Arthritis Study
Kurt de Vlam, Serge Steinfeld, Adrien Nzeusseu Toukap, Filip van den Bosch, Rik Joos, Piet Geysens, Hermine Leroi, Rik Lories the BEPAS Study Investigators
doi : 10.1093/rheumatology/keab233
Rheumatology, Volume 60, Issue 12, December 2021, Pages 5677–5685
To characterize the frequency of PsA subtypes, estimate the severity based on damage and inflammation and estimate the impact of PsA on patients’ health-related quality of life.
?-blocker prescription is associated with lower cumulative risk of knee osteoarthritis and knee pain consultations in primary care: a propensity score–matched cohort study
Georgina Nakafero, Matthew J Grainge, Ana M Valdes, Nick Townsend, Christian D. Mallen, Weiya Zhang, Michael Doherty, Mamas Mamas, Abhishek Abhishek
doi : 10.1093/rheumatology/keab234
Rheumatology, Volume 60, Issue 12, December 2021, Pages 5686–5696
To examine the association between ?-blocker prescription and first primary-care consultation for knee OA, hip OA, knee pain and hip pain.
Effectiveness and safety of mizoribine for the treatment of IgG4-related disease: a retrospective cohort study
Sho Fukui, Satoshi Kawaai, Takehiro Nakai, Masei Suda, Yukihiko Ikeda, Atsushi Nomura, Hiromichi Tamaki, Mitsumasa Kishimoto, Sachiko Ohde, Masato Okada
doi : 10.1093/rheumatology/keab235
Rheumatology, Volume 60, Issue 12, December 2021, Pages 5697–5704
Patients with IgG4-related disease (IgG4RD) usually require steroid-sparing agents due to relapse with tapering glucocorticoids (GC). We aimed to determine the efficacy and safety of mizoribine (MZR) among IgG4RD patients.
Drug survival of anakinra and canakinumab in monogenic autoinflammatory diseases: observational study from the International AIDA Registry
Jurgen Sota, Donato Rigante, Rolando Cimaz, Marco Cattalini, Micol Frassi, Raffaele Manna, Ludovico Luca Sicignano, Elena Verrecchia, Emma Aragona, Maria Cristina Maggio, Giuseppe Lopalco, Giacomo Emmi, Paola Parronchi, Alberto Cauli, Ewa Wiesik-Szewczyk, José Hernández-Rodríguez, Carla Gaggiano, Maria Tarsia, Mariam Mourabi, Gaafar Ragab, Antonio Vitale, Claudia Fabiani, Bruno Frediani, Vittoria Lamacchia, Alessandra Renieri, Luca Cantarini for the Autoinflammatory Diseases Alliance (AIDA) and the Autoinflammatory Diseases Working Group of the Italian Society of Rheumatology (SIR)
doi : 10.1093/rheumatology/keab419
Rheumatology, Volume 60, Issue 12, December 2021, Pages 5705–5712
To investigate survival of IL-1 inhibitors in monogenic autoinflammatory disorders (mAID) through drug retention rate (DRR) and identify potential predictive factors of drug survival from a real-life perspective.
Reliability, validity and responsiveness of physical activity monitors in patients with inflammatory myopathy
Bonny Rockette-Wagner, Didem Saygin, Siamak Moghadam-Kia, Chester Oddis, Océane Landon-Cardinal, Yves Allenbach, Sedin Dzanko, Diane Koontz, Nicole Neiman, Rohit Aggarwal
doi : 10.1093/rheumatology/keab236
Rheumatology, Volume 60, Issue 12, December 2021, Pages 5713–5723
Idiopathic inflammatory myopathies (IIMs) cause proximal muscle weakness, which affects the ability to carry out the activities of daily living. Wearable physical activity monitors (PAMs) objectively assess continuous activity and potentially have clinical usefulness in the assessment of IIMs. We examined the psychometric characteristics for PAM outcomes in IIMs.
Extracutaneous involvement is common and associated with prolonged disease activity and greater impact in juvenile localized scleroderma
Suzanne C Li, Gloria C Higgins, Mallory Chen, Kathryn S Torok, C Egla Rabinovich, Katie Stewart, Ronald M Laxer, Elena Pope, Kathleen A Haines, Marilynn Punaro, Kathleen M O’Neil on behalf of the Childhood Arthritis and Rheumatology Research Alliance Localized Scleroderma Clinical and Ultrasound Study group
doi : 10.1093/rheumatology/keab238
Rheumatology, Volume 60, Issue 12, December 2021, Pages 5724–5733
The aim of this study was to evaluate factors associated with extracutaneous involvement (ECI) in juvenile localized scleroderma (jLS).
Depression and anxiety symptoms at TNF inhibitor initiation are associated with impaired treatment response in axial spondyloarthritis
Sizheng Steven Zhao, Gareth T Jones, David M Hughes, Robert J Moots, Nicola J Goodson
doi : 10.1093/rheumatology/keab242
Rheumatology, Volume 60, Issue 12, December 2021, Pages 5734–5742
Depression and anxiety are associated with more severe disease in cross-sectional studies of axial spondyloarthritis (axSpA). We examined the association between baseline symptoms of depression or anxiety and response to TNF inhibitors (TNFi) in axSpA.
Retention rate and effectiveness of secukinumab vs TNF inhibitor in ankylosing spondylitis patients with prior TNF inhibitor exposure
Hong Ki Min, Hae-Rim Kim, Sang-Heon Lee, Yeon Sik Hong, Moon-Young Kim, Sung-Hwan Park, Kwi Young Kang
doi : 10.1093/rheumatology/keab245
Rheumatology, Volume 60, Issue 12, December 2021, Pages 5743–5752
The choice of second-line biologics for AS patients previously treated with a TNF inhibitor (TNFi) remains unclear. Here, we compared drug retention and clinical efficacy between AS patients who switched biologics to secukinumab and those who switched to a different TNFi.
Treatment strategies and safety of rechallenge in the setting of immune checkpoint inhibitors-related myositis: a national multicentre study
Amandine Weill, Julie Delyon, Vincent Descamps, Lydia Deschamps, Monica Dinulescu, Alain Dupuy, Philippe Célérier, Charlee Nardin, François Aubin, Yannick Le Corre, Valentine Heidelberger, Eve Maubec, Nausicaa Malissen, Christine Longvert, Laurent Machet, Valérie Gounant, Solenne Brosseau, Bertille Bonniaud, Géraldine Jeudy, Dimitri Psimaras, Ludovic Doucet, Céleste Lebbe, Gérard Zalcman, Adèle De Masson, Barouyr Baroudjian, Sarah Leonard-Louis, Baptiste Hervier, Florence Brunet-Possenti for the Groupe de Cancérologie Cutanée and PATIO Group
doi : 10.1093/rheumatology/keab249
Rheumatology, Volume 60, Issue 12, December 2021, Pages 5753–5764
The occurrence of immune-related myositis (irM) is increasing, yet there are no therapeutic guidelines. We sought to analyse the current therapeutic strategies of irM and evaluate the outcomes of immune checkpoint inhibitors (ICIs) rechallenge.
Comparing cost-utility of DMARDs in autoantibody-negative rheumatoid arthritis patients
Luurssen-Masurel Nathalie, Van Elise Mulligen, Weel Angelique Elisabeth Adriana Maria, Hazes Johanna Maria Wilhelmina, de Jong Pascal Hendrik Pieter the tREACH group investigators
doi : 10.1093/rheumatology/keab251
Rheumatology, Volume 60, Issue 12, December 2021, Pages 5765–5774
To evaluate the 1-year cost-effectiveness between three different initial treatment strategies in autoantibody-negative RA patients, according to 2010 criteria.
Tumour necrosis factor receptor-1 associated periodic syndrome (TRAPS)-related AA amyloidosis: a national case series and systematic review
Jérémie Delaleu, Samuel Deshayes, Francois Rodrigues, Lea Savey, Etienne Rivière, Nicolas Martin Silva, Achille Aouba, Serge Amselem, Marion Rabant, Gilles Grateau, Irina Giurgea, Sophie Georgin-Lavialle
doi : 10.1093/rheumatology/keab252
Rheumatology, Volume 60, Issue 12, December 2021, Pages 5775–5784
TNF receptor-1-associated periodic syndrome (TRAPS) is a rare autosomal dominant autoinflammatory disorder associated with mutations in the TNF receptor super family 1?A (TNFRSF1A) gene. AA amyloidosis (AA) is the most severe complication of TRAPS. To study the occurrence and prognosis of AA in TRAPS, we conducted a retrospective study of all French cases and a systematic literature review.
What is the incidence of methotrexate or leflunomide discontinuation related to cytopenia, liver enzyme elevation or kidney function decline?
Georgina Nakafero, Matthew J Grainge, Tim Card, Christian D Mallen, Weiya Zhang, Michael Doherty, Maarten W Taal, Guruprasad P Aithal, Abhishek Abhishek
doi : 10.1093/rheumatology/keab254
Rheumatology, Volume 60, Issue 12, December 2021, Pages 5785–5794
To examine incidence of treatment changes due to abnormal blood-test results and, to explore rates of treatment changes due to liver, kidney and haematological blood-test abnormalities in autoimmune rheumatic diseases (AIRD) treated with low-dose MTX or LEF.
Similar biologic drug response regardless of radiographic status in axial spondyloarthritis: data from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis registry
Xabier Michelena, Sizheng Steven Zhao, Sayam Dubash, Linda E Dean, Gareth T Jones, Helena Marzo-Ortega
doi : 10.1093/rheumatology/keab070
Rheumatology, Volume 60, Issue 12, December 2021, Pages 5795–5800
To describe the baseline characteristics, biologic DMARD (bDMARD) response and drug survival of axial SpA (axSpA) patients in the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis (BSRBR-AS) according to radiographic status.
JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study
Tom Le Voyer, Cyril Gitiaux, François-Jérôme Authier, Christine Bodemer, Isabelle Melki, Pierre Quartier, Florence Aeschlimann, Arnaud Isapof, Jean Philippe Herbeuval, Vincent Bondet, Jean-Luc Charuel, Marie-Louise Frémond, Darragh Duffy, Mathieu P Rodero, Brigitte Bader-Meunier
doi : 10.1093/rheumatology/keab116
Rheumatology, Volume 60, Issue 12, December 2021, Pages 5801–5808
To evaluate the efficacy and safety of Janus kinase inhibitors (JAKis) in JDM.
Prevalence and real-world management of vedolizumab-associated enthesitis in successfully treated IBD patients
Mirko Di Ruscio, Ilaria Tinazzi, Angela Variola, Andrea Geccherle, Antonio Marchetta, Dennis McGonagle
doi : 10.1093/rheumatology/keab135
Rheumatology, Volume 60, Issue 12, December 2021, Pages 5809–5813
Some studies have reported the development of moderate and severe de novo SpA-associated disease under vedolizumab (VDZ) treatment for IBD. Herein, we report a case series who developed severe enthesitis under VDZ therapy from a cohort of 90 treated cases.
A clinical comparison of an endothelin receptor antagonist and phosphodiesterase type 5 inhibitors for treating digital ulcers of systemic sclerosis
Sung Hae Chang, Jae Bum Jun, Yun Jong Lee, Tae Young Kang, Ki Won Moon, Ji Hyeon Ju, Seong Wook Kang, In Ah Choi, Yong-Beom Park, Seung Geun Lee, Shin-Seok Lee, Nam Hun Heo, Eun Bong Lee
doi : 10.1093/rheumatology/keab147
Rheumatology, Volume 60, Issue 12, December 2021, Pages 5814–5819
To assess the efficacy of an endothelin receptor antagonist (ERA) and phosphodiesterase type5 inhibitors (PDE5is) for treating SSc-related digital ulcers (DUs).
IL11 is elevated in systemic sclerosis and IL11-dependent ERK signalling underlies TGF?-mediated activation of dermal fibroblasts
Eleonora Adami, Sivakumar Viswanathan, Anissa A Widjaja, Benjamin Ng, Sonia Chothani, Nevin Zhihao, Jessie Tan, Pei Min Lio, Benjamin L George, Umut Altunoglu, Kakaly Ghosh, Bhairav S Paleja, Sebastian Schafer, Bruno Reversade, Salvatore Albani, Andrea Low Hsiu Ling, Steven O'Reilly, Stuart A Cook
doi : 10.1093/rheumatology/keab168
Rheumatology, Volume 60, Issue 12, December 2021, Pages 5820–5826
Interleukin 11 (IL11) is highly upregulated in skin and lung fibroblasts from patients with systemic sclerosis (SSc). Here we tested whether IL11 is mechanistically linked with activation of human dermal fibroblasts (HDFs) from patients with SSc or controls.
Retinal microcirculation abnormalities in patients with systemic sclerosis: an explorative optical coherence tomography angiography study
Adriano Carnevali, Giuseppe Giannaccare, Valentina Gatti, Caterina Battaglia, Giorgio Randazzo, Angeli Christy Yu, Marco Pellegrini, Francesco Ferragina, Mario Damiano Toro, Caterina Bruno, Vincenzo Scorcia, Francesco Ursini
doi : 10.1093/rheumatology/keab258
Rheumatology, Volume 60, Issue 12, December 2021, Pages 5827–5832
To investigate subclinical and clinical abnormalities in retinal and choroidal vascular plexuses in patients with SSc by means of optical coherence tomography angiography (OCT-A).
TSP1 is the essential domain of SEMA5A involved in pannus formation in rheumatoid arthritis
Chipeng Xiao, Chen Lv, Siyuan Sun, Heping Zhao, Hanzhi Ling, Man Li, Yang Qin, Jinhao Zhang, Jianguang Wang, Xinyu Yang
doi : 10.1093/rheumatology/keab133
Rheumatology, Volume 60, Issue 12, December 2021, Pages 5833–5842
In this study, we explored the effect of semaphorin5A (SEMA5A) on RA pathogenesis and its specific TSP1 domain on pannus formation.
Expression of sterile-? and armadillo motif containing protein (SARM) in rheumatoid arthritis monocytes correlates with TLR2-induced IL-1? and disease activity
Ryan S Thwaites, Sarah Unterberger, Giselle Chamberlain, Henry Gray, Kelsey Jordan, Kevin A Davies, Neil A Harrison, Sandra Sacre
doi : 10.1093/rheumatology/keab162
Rheumatology, Volume 60, Issue 12, December 2021, Pages 5843–5853
Cartilage and bone damage in RA are associated with elevated IL-1?. The effects of IL-1? can be reduced by biological therapies that target IL-1? or TNF-?. However, the mechanisms responsible for increased IL-1? and the effect of anti-TNF-? have not been fully elucidated. Recently, sterile-? and armadillo motif containing protein (SARM) was identified as a negative regulator of toll-like receptor (TLR) induced IL-1? secretion through an interaction with the inflammasome. This study set out to investigate SARM during TLR-induced IL-1? secretion in RA peripheral blood monocytes and in patients commencing anti-TNF-? treatment.
Exposure–response analysis for selection of optimal dosage regimen of anifrolumab in patients with systemic lupus erythematosus
Yen Lin Chia, Linda Santiago, Bing Wang, Denison Kuruvilla, Shiliang Wang, Raj Tummala, Lorin Roskos
doi : 10.1093/rheumatology/keab176
Rheumatology, Volume 60, Issue 12, December 2021, Pages 5854–5862
The randomized, double-blind, phase 2?b MUSE study evaluated the efficacy and safety of the type I IFN receptor antibody anifrolumab (300?mg or 1000?mg every 4?weeks) compared with placebo for 52?weeks in patients with chronic, moderate to severe SLE. Characterizing the exposure–response relationship of anifrolumab in MUSE will enable selection of its optimal dosage regimen in two phase 3 studies in patients with SLE.
TRIM33 gene somatic mutations identified by next generation sequencing in neoplasms of patients with anti-TIF1? positive cancer-associated dermatomyositis
Nadège Cordel, Céline Derambure, Sophie Coutant, Xavier Mariette, Denis Jullien, Sébastien Debarbieux, Olivier Chosidow, Alain Meyer, Didier Bessis, Pascal Joly, Alexis Mathian, Hervé Levesque, Jean-Christophe Sabourin, Isabelle Tournier, Olivier Boyer, the OncoMyositis Study group
doi : 10.1093/rheumatology/keab260
Rheumatology, Volume 60, Issue 12, December 2021, Pages 5863–5867
To deep sequence the TRIM33 gene in tumours from patients with cancer-associated anti-TIF1? autoantibody-positive dermatomyositis (DM) as TRIM33 somatic mutations in tumours may trigger this auto-immune disease.
Detection of radiographic sacroiliitis with an artificial neural network in patients with suspicion of axial spondyloarthritis
Denis Poddubnyy, Fabian Proft, Kay-Geert A Hermann, Laura Spiller, Stefan M Niehues, Lisa C Adams, Mikhail Protopopov, Valeria Rios Rodriguez, Burkhard Muche, Judith Rademacher, Murat Torgutalp, Keno K Bressem, Janis L Vahldiek
doi : 10.1093/rheumatology/keab636
Rheumatology, Volume 60, Issue 12, December 2021, Pages 5868–5869
Expression of parathormone receptor on B-lymphocytes in systemic lupus erythematosus and Sjögren’s syndrome
Lady J Rios-Serna, Ivana Nieto-Aristizábal, Ingrid Ruiz-Ordoñez, Tatiana Mendez-Rayo, Iván Posso-Osorio, Jhon García, Erika P Navarro, María Claudia Barrera, David Aguirre-Valencia, Carlos A Cañas, Gabriel J Tobón
doi : 10.1093/rheumatology/keab693
Rheumatology, Volume 60, Issue 12, December 2021, Pages 5869–5872
Impact of latent tuberculosis treatment on the risk of mycobacterium tuberculosis (MTB) in seropositive rheumatoid arthritis initiating TNF inhibitors in an MTB endemic area
Dong Won Park, Yun Jin Kim, Yoon-Kyoung Sung, Sung Jun Chung, Yoomi Yeo, Tai Sun Park, Hyun Lee, Ji-Yong Moon, Sang-Heon Kim, Tae-Hyung Kim, Ho Joo Yoon, Jang Won Sohn
doi : 10.1093/rheumatology/keab749
Rheumatology, Volume 60, Issue 12, December 2021, Pages 5872–5874
Synovial chondromatosis of the knee: three different imaging methods
Ana Sofia Pinto, Francisca Guimarães, Hugo Parente, Soraia Azevedo, Daniela Santos-Faria, Filipa Teixeira
doi : 10.1093/rheumatology/keab240
Rheumatology, Volume 60, Issue 12, December 2021, Page 5832
Hypocomplementemic urticarial vasculitis syndrome revealed by bilateral sudden sensorineural hearing loss
Guillaume Poillon, Daniel Levy, Augustin Lecler, Thomas Sené
doi : 10.1093/rheumatology/keab131
Rheumatology, Volume 60, Issue 12, December 2021, Page 5875
Toxic epidermal necrolysis-like acute cutaneous lupus/acute syndrome of apoptotic pan-epidermolysis
Tajamul H Mir, Irfan A Bhat, Bushra Jabeen, Mir Laieeq I Haji
doi : 10.1093/rheumatology/keab185
Rheumatology, Volume 60, Issue 12, December 2021, Pages 5876–5877
Bilateral rhabdomyolysis of the arms after an extensive horse ride
Martin Krusche, Udo Schneider, Sarah Keller
doi : 10.1093/rheumatology/keab244
Rheumatology, Volume 60, Issue 12, December 2021, Page 5878
Hereditary multiple osteochondromatosis: a familial case of an unusual pathology
Ana Isabel Maduro, André Pinto Saraiva, Armando Malcata, Margarida Coutinho
doi : 10.1093/rheumatology/keab259
Rheumatology, Volume 60, Issue 12, December 2021, Page 5879
Cutaneous ulceration and digital gangrene in an anti-MDA5-positive overlap myositis
Antao Xu, Xia Lv, Fang Du, Min Dai
doi : 10.1093/rheumatology/keab284
Rheumatology, Volume 60, Issue 12, December 2021, Pages 5880–5881
Corrigendum to: Increased risk of cardiovascular disease in giant cell arteritis: a general population-based study
Neda Amiri, Mary De Vera, Hyon K Choi, Eric C Sayre, J Antonio Avina-Zubieta
doi : 10.1093/rheumatology/keab299
Rheumatology, Volume 60, Issue 12, December 2021, Page 5882
Corrigendum to: Comparative study of obstetric antiphospholipid syndrome (OAPS) and non-criteria obstetric APS (NC-OAPS): report of 1640 cases from EUROAPS registry
Jaume Alijotas-Reig, Enrique Esteve-Valverde, Raquel Ferrer-Oliveras, Luis Sáez-Comet, Elmina Lefkou, Arsène Mekinian, Cristina Belizna, Amelia Ruffatti, Ariela Hoxha, Angela Tincani, Cecilia Nalli, Luca Marozio, Aldo Maina, Gerard Espinosa, Roberto Ríos-Garcés, Ricard Cervera, Sara De Carolis, Giuseppina Monteleone, Omar Latino, Sebastian Udry, Elisa LLurba, Carmen Garrido-Gimenez, Laura Trespidi, Maria Gerosa, Cecilia Beatrice Chighizola, Patrizia Rovere-Querini, Valentina Canti, Karoline Mayer-Pickel, Sara Tabacco, Anna Arnau, Jaume Trapé, Domingo Ruiz-Hidalgo, Laia Sos, Inmaculada Farran-Codina for the EUROAPS Study Group
doi : 10.1093/rheumatology/keab659
Rheumatology, Volume 60, Issue 12, December 2021, Page 5883
How reflectance confocal microscopy can be used?in systemic sclerosis skin diagnosis
Sara Mazzilli, Stella Modica, Elisabetta Greco, Roberto Perricone, Elena Campione, Luca Bianchi
doi : 10.1093/rheumatology/keab241
Rheumatology, Volume 60, Issue 12, December 2021, Pages e427–e428
Somatic mutation in RUNX1 underlies mucocutaneus inflammatory manifestations
Tsubasa Okano, Akira Nishimura, Kento Inoue, Takuya Naruto, Shown Tokoro, Takahiro Tomoda, Takahiro Kamiya, Asami Simbo, Yuko Akutsu, Keisuke Okamoto, Tzuwen Yeh, Takeshi Isoda, Masakatsu Yanagimachi, Michiko Kajiwara, Kohsuke Imai, Hirokazu Kanegane, Masaaki Mori, Tomohiro Morio, Masatoshi Takagi
doi : 10.1093/rheumatology/keab513
Rheumatology, Volume 60, Issue 12, December 2021, Pages e429–e431
Granulomatous large vessel phlebitis in sarcoidosis
Robert Biesen, Markus Lerchbaumer, Jan-Paul Frese, Désirée Schaumburg, Maximilian Dölling, Malte C Kleinschmidt, Gerd-Rüdiger Burmester, Christian Furth, Werner Stenzel, Udo Schneider
doi : 10.1093/rheumatology/keab519
Rheumatology, Volume 60, Issue 12, December 2021, Pages e432–e434
Atypical splice-site mutations causing VEXAS syndrome
Marie Templé, Eugénie Duroyon, Carolyne Croizier, Julien Rossignol, Thomas Huet, Chloé Friedrich, Loria Zalmai, Pascal Priollet, Gilles Hayem, Olivier Tournillhac, Guillaume Le Guenno, Olivier Hermine, Benjamin Terrier, Olivier Kosmider
doi : 10.1093/rheumatology/keab524
Rheumatology, Volume 60, Issue 12, December 2021, Pages e435–e437
Polyarthritis and fever—a clinical conundrum
Helena Assunção, Ana R Prata, Jorge Silva, Armando Malcata
doi : 10.1093/rheumatology/keab592
Rheumatology, Volume 60, Issue 12, December 2021, Pages e438–e440
Gout presenting as a chronic inflammatory arthritis from immune checkpoint inhibitors: case series
Kevin Lee, Shokrollah Elahi, Siavash Mashhouri, Carrie Ye
doi : 10.1093/rheumatology/keab608
Rheumatology, Volume 60, Issue 12, December 2021, Pages e441–e443
Genitourinary involvement of immunoglobulin G4–related disease
Rainjade Chung, Miyad Movassaghi, George Moran, Derek Jones, Kelly D Steed, Christopher B Anderson
doi : 10.1093/rheumatology/keab614
Rheumatology, Volume 60, Issue 12, December 2021, Pages e444–e446
Reversible basal ganglia lesions in a patient with systemic lupus erythematosus
Yoshiyuki Arinuma, Hirotomo Asakura, Kunihiro Yamaoka
doi : 10.1093/rheumatology/keab621
Rheumatology, Volume 60, Issue 12, December 2021, Pages e447–e449
Myxovirus resistance protein 1–expressing fatal myocarditis in a patient with anti-MDA5 antibody–positive dermatomyositis
Rika Sakamoto, Yorihisa Kotobuki, Saki Iga, Satoshi Nojima, Rikako Deno, Yuma Hanaoka, Kyoko Tonomura, Eiji Kiyohara, Yukinobu Nakagawa, Ikuko Ueda-Hayakawa, Noriko Arase, Manabu Fujimoto
doi : 10.1093/rheumatology/keab637
Rheumatology, Volume 60, Issue 12, December 2021, Pages e450–e452
Comment on: Comorbidities (excluding lymphoma) in Sjögren’s syndrome
Ciro Manzo, Jordi Serra-Mestres, Marco Isetta
doi : 10.1093/rheumatology/keab602
Rheumatology, Volume 60, Issue 12, December 2021, Pages e453–e454
Comment on: Comorbidities (excluding lymphoma) in Sjögren’s syndrome. Reply
José M Pego-Reigosa, Íñigo Rúa-Figueroa Fernández de Larrinoa
doi : 10.1093/rheumatology/keab603
Rheumatology, Volume 60, Issue 12, December 2021, Page e455
Rectracted: Anti-ribosomal-phosphoprotein autoantibodies penetrate to neuronal cells via neuronal growth associated protein, affecting neuronal cells in vitro
Shaye Kivity, Yehuda Shoenfeld, Maria-Teresa Arango, Dolores J Cahill, Sara Louise O’Kane, Margalit Zusev, Inna Slutsky, Michal Harel-Meir, Joab Chapman, Torsten Matthias, Miri Blank
doi : 10.1093/rheumatology/kew027
Rheumatology, Volume 60, Issue 12, December 2021, Pages e456–e466
Anti-ribosomal-phosphoprotein antibodies (anti-Ribos.P Abs) are detected in 10–45% of NPSLE patients. Intracerebroventricular administration of anti-ribosomal-P Abs induces depression-like behaviour in mice. We aimed to discern the mechanism by which anti-Ribos.P Abs induce behavioural changes in mice.
